ITIH5 and invasive breast carcinoma: We initially assessed promoter methylation of SPAG6, PER1, NKX2-6 and ITIH5 in a serum cohort consisting of samples of women with benign disease (n = 34), DCIS (n = 27) and early invasive breast cancer (n = 42).